Problem

Scoop addresses the slow, expensive document-assembly bottleneck that biotechs face before they can begin human drug trials. Companies must consolidate study, manufacturing, and supporting data from internal teams and contractors into a coherent IND submission, repeatedly rewriting information across documents and checking that every section remains consistent. Scoop’s launch materials say this process can take months, delay first-in-human studies, waste money before a patient is treated, and cost more than $100,000 in CRO fees per submission; they claim a typical biotech could reach human trials two to five months sooner.

The clearest killer use case is preparing an initial IND quickly enough to move a drug from preclinical development into first-in-human testing. The same pain recurs afterward as new study results, manufacturing changes, amendments, and annual-report updates require teams to revisit and reconcile the submission.

Product / Service

Scoop is an AI platform for preclinical regulatory submissions, positioned around AI-native drafting and continuous maintenance rather than one-off document generation. It ingests scientific reports, CMC packages, and supporting documents, maps their contents to the IND structure, generates submission-ready narratives with source-level traceability, and flags conflicting values or outdated language.

The product turns static files into a continuously updated regulatory workspace: when new studies or manufacturing changes arrive, it identifies affected sections and regenerates the relevant text. The intended benefit is to let regulatory teams review and approve content while spending less time assembling, cross-referencing, and manually maintaining documents. Scoop claims this can compress IND assembly from months to days while reducing inconsistency and rejection risk.

Market

Scoop operates in life-sciences regulatory technology, at the intersection of regulatory-affairs software, clinical-trial workflow automation, and generative AI for regulatory writing. Its differentiation is upstream automation of IND content creation and ongoing reconciliation. It competes for adjacent workflow spend with established submission and eCTD platforms such as Veeva Submissions, Certara GlobalSubmit, EXTEDO, Freyr, LORENZ, and MasterControl, as well as with CROs that perform regulatory-document preparation. Those incumbents generally emphasize submission planning, authoring, review, approval, lifecycle management, or eCTD publishing, while Scoop emphasizes AI-generated drafts tied directly to source data and continuously maintained as the science changes.

Public evidence indicates an early-stage company rather than a scaled commercial vendor. Y Combinator lists Scoop as founded in 2025, in its Fall 2025 batch, active, and staffed by a two-person team. Its launch post asks for introductions to regulatory leaders at biotechs and CROs, while the available company materials do not disclose named customers, revenue, or funding; Scoop is therefore best characterized as pre-revenue or in early commercialization, with product positioning and an enterprise, demo-led sales motion but no publicly demonstrated revenue traction.